Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

  title={Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer},
  author={S. Tolaney and C. Savulsky and G. Aktan and D. Xing and A. Almonte and V. Karantza and S. Diab},
  journal={European Journal of Cancer},
Checkpoint blockade in the treatment of breast cancer: current status and future directions
The current evidence for PD-1/PD-L1 blockade in metastatic triple-negative breast cancer (TNBC), HER2+ breast cancer and ER+ disease, as well as the emerging evidence for use in the early-stage (neoadjuvant) setting are discussed. Expand
Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials
Investigation of the efficacy of novel IO agents in patients with metastatic breast cancer, beyond TNBC, treated in phase I clinical trials at the University of Colorado shows benefit from IO therapy that was not limited to patients with TNBC and confirms improved efficacy from IO agent in combination with chemotherapy. Expand
Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
  • Yihang Qi, Lin Zhang, +4 authors Jing Wang
  • Medicine
  • Frontiers in Pharmacology
  • 2021
Anti-PD-1/PD-L1 monotherapy showed a manageable safety profile and had a promising and durable anti-tumor efficacy in metastatic breast cancer patients and higher PD-L 1 expression may be closely correlated to a better clinical efficacy. Expand
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
It is revealed that provider-assessed AEs can vary greatly from patient experiences, and future studies should incorporate CTCAE and PRO instruments to improve reporting of treatment-related AEs. Expand
An overview of immune checkpoint inhibitors in breast cancer
Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option inExpand
Breast Cancer Immunotherapy: From Biology to Current Clinical Applications
Therapeutic strategies for the treatment of breast cancer have historically been determined by the presence or absence of hormone receptors and HER2 amplification and/or protein expression. ForExpand
Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
The immunotherapy might be a promising therapeutic strategy for breast cancer and several clinical trials are still on-going, which highlights the need to develop combinations of PD-1/PD-L1 inhibitors with chemotherapy, molecularly targeted therapies, and other immunotherapies to maximize the clinical efficacy. Expand
Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)
A Chinese expert group has analyzed, summarized, and discussed related research data on the diagnosis, treatment, and prognosis of inoperable, locally advanced Breast cancer and recurrent or metastatic breast cancer and has developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018). Expand
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
The addition of pembrolizumab to eribulin did not improve progression-free survival, objective response rate (ORR) and overall survival (OS), and exploratory analyses assessed the association between PFS and PD-L1 status, tumor-infiltrating lymphocytes (TILs, tumor mutational burden, and genomic alterations. Expand
Efficacy and Safety of Pembrolizumab Based Therapies in Triple-Negative Breast Cancer: A Systematic Review of Clinical Trials.
Pembrolizumab was more effective in the treatment of early-stage TNBC patients as compared to placebo, regardless of PD-L1 status, and in advanced-stage breast cancer, pembrolizer was as effective as single-agent chemotherapy with a better safety profile. Expand